Abstract
Migraine management in children relies on understanding the difference between adult and childhood migraine, being able to identify childhood migraine variants and knowledge of both the pediatric and adult literature regarding treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Levin M. The international classification of headache disorders, 3rd edition (ICHD III)—changes and challenges. Headache: J Head Face Pain. 2013;53:1383–95. doi:10.1111/head.12189.
Cologno D, Torelli P, Manzoni GC. Migraine with aura: a review of 81 patients at 10–20 years’ follow-up. Cephalalgia. 1998;18:690–6.
Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter: pharmacological treatment of migraine headache in children and adolescents. Neurology. 2004;63:2215–24.
Hershey AD, Powers SW, Bentti AL, et al. Standard dosing of amitriptyline is highly effective in a pediatric headache center population. Headache. 1999;39:357–8.
Winner P, Pearlman EM, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45(10):1304–12.
Lewis D, Winner P, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics. 2009;123(3):924–34.
Bakola E, Skapinakis P, Tzoufi M, Damigos D, Mavreas V. Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review. Eur J Pain. 2009;13(9):893–901.
Caruso JM, Brown WD, et al. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache. 2000;40(8):672–6.
Serdaroglu G, Erhan E, et al. Sodium valproate prophylaxis in childhood migraine. Headache. 2002;42(8):819–22.
Apostol G, Cady RK, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache. 2008;48(7):1012–25.
Mulleners WM, McCrory DC, Linde M. Antiepileptics in migraine prophylaxis: An updated Cochrane review. Cephalalgia. 2014. Evaluated the efficacy of anticonvulsants used in the migraine population and the evidence supporting their use.
Buse D, Manack A, Fanning K, Serrano D, Reed M, Turkel C, et al. Chronic migraine prevalence, disability, and socioeconomic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–70. Demonstrates the difficulties this condition places on each individual patient. Children missing school are also missing social experiences as well as learning opportunies.
Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.
Bigal M, Rapoport A, Sheftell F, et al. The International Classification of Headache Disorders revised criteria for chronic migraine – field testing in a headache specialty clinic. Cephalalgia 2007;230–234.
Chan V, Mccabe J, MacGregor D. Botox treatment for migraine and chronic daily headache in adolescents. J Neurosc Nurs. 2009;41(5):235–43.
Ahmed K, Oas K, Mack K, Garza I. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010;43:316–9.
Bernhard MK, Bertsche A, Syrbe S, Weise S, Merkenschlager A. Botulinum toxin injections for chronic migraine in adolescents—an early therapeutic option in the transition from neuropaediatrics to neurology. Fortschr Neurol Psychiatr. 2014;82(1):39–42. This is a promising treatment for the pediatric population with chronic migraine. It has been approved in adults and is now being also included in the pediatric population.
Kabbouche M, O’Brien H, Hershey AD. Onabotulinum toxin A in pediatric chronic daily headache. Curr Neurol Neurosci Rep. 2012;12:114–7.
Arruda MA, Guidetti V, Galli F, et al. Primary headaches in childhood—a population-based study. Cephalalgia. 2010;30:1056–64.
Fleisher DR. Cyclic vomiting syndrome and migraine. J Pediatr. 1999;134:533–5.
Moses J, Keilman A, Worley S, Radhakrishnan K, Rothner AD, Parikh S. Approach to the diagnosis and treatment of cyclic vomiting syndrome: a large single-center experience with 106 patients. Pediatr Neurol. 2014;50(6):569–73. Improved understanding of timing of onset and details abnormal lab values that suggest related abnormalities that these patients have which may lead to better understanding and therefore improve treatment.
Farquar HA. Abdominal migraine in children. BMJ. 1956;i:1082–5.
Russell G et al. Abdominal migraine: evidence for existence and treatment options. Pediatr Drugs. 2002;4:1–8.
Drigo P, Carli G, Laverda AM. Benign paroxysmal vertigo of childhood. Brain Dev (Netherlands). 2001;23:38–41.
Worawattanakul M et al. Abdominal migraine: prophylactic treatment and follow-up. J Pediatr Gastroenerol Nutr. 1999;28:37–49.
Drigo P, Carli G, Laverda AM. Benign paroxysmal torticollis of infancy. Brain Dev. 2000;22:169–72.
Herman MJ. Torticollis in infants and children: common and unusual causes. Instr Course Lect. 2006;55:647–53.
Compliance with Ethics Guidelines
Conflict of Interest
Tara Mangum declares that she has no conflict of interest. Marcy Yonker has received consultancy fees from Amgen and grants from NINDS, Allergan, and Astra-Zeneca.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Headache
Rights and permissions
About this article
Cite this article
Yonker, M., Mangum, T. Migraine Management in Children. Curr Neurol Neurosci Rep 15, 20 (2015). https://doi.org/10.1007/s11910-015-0540-6
Published:
DOI: https://doi.org/10.1007/s11910-015-0540-6